RESI Panel Announcement: Large Pharma Firms Looking Externally For New Assets

7 Apr

By Christine A. Wu, Research Analyst, LSN

chrsitine

Large pharma companies are increasingly looking to early stage companies to fill their future pipelines. These firms have a variety of means of engaging with early stage companies, including in-licensing, collaborations, equity investments, and M&A. At RESI@TMCx, four senior external sourcing staff from the pharma world will explain what their firms are looking for, how they work with early stage companies, and how an emerging biotech company can position themselves to make a big pharma deal.

Moderated by Bill Kohlbrenner, CSO, Life Science Nation, the panelists are:

  • Marc Schwabish, US Head, Pharma Business Development & Licensing, Bayer
  • Barbara Araneo, Innovation Sourcing Director, Novo Nordisk
  • Joseph Simeone, Director, Business Development & Licensing, Merck
  • Mark Day, Executive Director, Head of External Research & Scouting, Alexion

RESI-Houston-2016_600

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: